These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Total androgen ablation: American experience.
    Author: Crawford ED, Nabors WL.
    Journal: Urol Clin North Am; 1991 Feb; 18(1):55-63. PubMed ID: 1899495.
    Abstract:
    In conclusion, the intergroup study in the US, as well as preliminary results of the Anandron and leuprolide study, would support the view that combined androgen blockade is better than monotherapy in achieving clinical responses, prolonging the time to progression, and improving the survival rate. This improvement in survival rate is not a huge advance but is a step in the right direction. Future clinical trials are needed to evaluate newer methods to improve survival rates. The results also open up the possibility of employing this combined androgen blockade in earlier stages of prostate cancer in order to delay progression of the cancer and perhaps improve patient survival. Only carefully constructed clinical trials will be able to answer these questions.
    [Abstract] [Full Text] [Related] [New Search]